Opus Genetics (Nasdaq: IRD) reported that its Board’s Compensation Committee approved equity awards under the company’s 2021 Inducement Plan, as amended, as a material inducement to hiring three new non-executive employees. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards consist of options to purchase an aggregate of 310,000 shares of Opus Genetics common stock, with an exercise price equal to the fair market value on the grant date. The options vest over four years: 25% on the one-year anniversary of each hire date, and the remaining 75% in quarterly installments thereafter, subject to possible acceleration or forfeiture under the applicable award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
IRD has an active S-3 shelf dated August 6, 2026, with reported usage count of 0. Against that finan...
Analysis
IRD has an active S-3 shelf dated August 6, 2026, with reported usage count of 0. Against that financing capacity, the inducement awards add potential dilution, while recent insider activity was net selling.
Key Figures
Employees receiving awards:3 employeesOption shares:310,000 sharesVesting period:4 years+2 more
The company was added to three Russell indexes effective June 29.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive or informational clinical updates mostly diverged from subsequent negative price reactions, while the Russell index inclusion aligned positively.
"awards under the Company’s 2021 Inducement Plan, as amended"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
nasdaq listing rule 5635(c)(4)regulatory
"approved in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
fair market valuefinancial
"exercise price equal to the fair market value of an underlying share"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
vestingfinancial
"vest over a period of four years, with 25% vesting on the one-year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to three non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted in the form of options to purchase an aggregate of 310,000 shares of the Company’s common stock. The option awards have an exercise price equal to the fair market value of an underlying share of Company common stock as of the grant date and vest over a period of four years, with 25% vesting on the one-year anniversary of the hire date and the remaining 75% vesting in quarterly installments thereafter, subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the applicable award agreement.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts
Investors Jenny Kobin Remy Bernarda IR Advisory Solutions ir@opusgtx.com
Media Kimberly Ha KKH Advisors 917-291-5744 kimberly.ha@kkhadvisors.com
FAQ
What inducement grants did Opus Genetics (Nasdaq: IRD) announce on August 19, 2026?
Opus Genetics announced stock option inducement grants covering an aggregate of 310,000 shares for three new non-executive employees. According to the company, these awards were approved under its 2021 Inducement Plan as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4).
How many Opus Genetics (IRD) shares are covered by the new inducement stock options?
The new inducement stock options cover an aggregate of 310,000 shares of Opus Genetics common stock. According to the company, these options were granted to three non-executive employees as part of their hiring packages under the 2021 Inducement Plan, as amended.
What are the vesting terms for the Opus Genetics (IRD) inducement option grants?
The inducement options vest over four years. According to Opus Genetics, 25% vests on the one-year anniversary of each employee’s hire date, with the remaining 75% vesting in quarterly installments thereafter, subject to possible acceleration or forfeiture under the award agreements.
How is the exercise price determined for the new Opus Genetics (IRD) inducement options?
The exercise price is set at the fair market value of Opus Genetics common stock on the grant date. According to the company, this pricing applies to the inducement options granted under the 2021 Inducement Plan for the three newly hired non-executive employees.
Who received the August 19, 2026 inducement equity awards from Opus Genetics (IRD)?
The inducement equity awards were granted to three non-executive employees who were not previously employees or directors. According to Opus Genetics, these options were approved by the Board’s Compensation Committee as a material inducement to their employment under Nasdaq Listing Rule 5635(c)(4).
